4D Molecular Therapeutics, a late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, entered into a strategic credit facility agreement with Hercules Capital for up to $200 million.
“Our strong cash, cash equivalents and marketable securities position, excluding this strategic credit facility, is expected to continue to fund our planned operations into the second half of 2028. Access to this non-dilutive capital further increases our financial strength, providing the Company with strategic and operational flexibility,” Kristian Humer, chief financial officer of 4DMT, said. “The credit facility diversifies our capital structure, allowing us to focus on sustaining our execution momentum, growth planning across our innovative gene therapy pipeline and early commercial planning for 4D-150.”
Lake McGuire, managing director at Hercules Capital, added, “Hercules Capital is pleased to support 4DMT with a flexible financing solution as the Company advances 4D-150 through Phase 3 development and pre-commercial planning in wet AMD and DME. This partnership reflects our commitment to backing innovative genetic medicines with the potential to transform treatment paradigms for patients with serious unmet needs.”
Under the terms of the agreement, 4DMT drew an initial $20 million at closing. An additional $30 million is available, at the company’s option, through June 15, 2027, with an additional $100 million available upon the company’s achievement of certain milestones, and the remaining $50 million available subject to final lender approval.
Leerink Partners served as the exclusive financial advisor to 4DMT on the strategic credit facility.
